Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label extension and safety monitoring of etrolizumab in moderate to severe ulcerative colitis
2013-004435-72Phase 3Unknown
- Sponsor
- Roche
- Start
- Jul 2014
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of Etrolizumab in autoimmune colitis, sponsored by Roche. Primary endpoints: Long-term efficacy by partial Mayo Clinic Score and Long-term safety of etrolizumab. Status: unknown.
02
Drugs
Etrolizumab
03
Conditions
autoimmune colitis
Beyond the preview
Go deeper on 2013-004435-72.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-004435-72.